Clinical Trials
210
23 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1834
Active, not recruiting
13
6.2%
Completed
132
62.9%
Enrolling By Invitation
2
0.9%
Not yet recruiting
8
3.8%
Recruiting
43
20.5%
Suspended
3
1.4%
Terminated
6
2.9%
Unknown
1
0.5%
Withdrawn
2
0.9%
No approval data available
- Researchers at the University of Bern, ETH Zurich, and ZHAW developed an enzyme-based method to build DNA-encoded libraries under mild, water-based conditions without damaging DNA barcodes. - The team used engineered CoA ligases and N-acyltransferases to synthesize over 120 diverse DNA-barcoded molecules, expanding the chemical space accessible in early-stage drug discovery. - The approach combines enzymatic and classical chemical methods, enabling reactions previously too harsh for sensitive DNA tags and increasing library diversity. - Published in Nature Catalysis, the study highlights potential gains in efficiency, cost-effectiveness, and sustainability for small-molecule drug development.
- A new Cochrane review of 12 randomized controlled trials involving nearly 23,000 people with cardiovascular disease found that low-dose colchicine significantly reduced heart attacks and strokes. - For every 1,000 people treated with colchicine, there were 9 fewer heart attacks and 8 fewer strokes compared to those not receiving the drug. - The anti-inflammatory gout medication showed no serious adverse events, with only mild and short-lived digestive side effects reported. - Among 200 cardiovascular disease patients, low-dose colchicine could prevent approximately two heart attacks and two strokes that would normally be expected.
- Excellergy secured $70 million in Series A funding to develop first-in-class trifunctional Effector Cell Response Inhibitors (ECRIs) for allergic conditions. - The company's ECRIs employ a novel mechanism that removes IgE bound to receptors, neutralizes free IgE, and downregulates receptor expression simultaneously. - Phase 1 trials are planned for early 2026, with food allergies and chronic urticaria identified as top targets for Phase 2 development. - Supporting preclinical data published in Journal of Allergy and Clinical Immunology demonstrates the ability to remove receptor-bound IgE without triggering cell activation.
